A Phase 3 interventional study of Elacestrant and Standard of Care in Breast Cancer, sponsored by Stemline Therapeutics, Inc.. Completed at 244 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing elacestrant in Breast Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. elacestrant · Breast Neoplasms.
Among the 24 studies testing elacestrant in Breast Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 3rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →15 of the 24 studies testing elacestrant in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Stemline Therapeutics, Inc. · Sites in Japan
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+ · Women only
European Institute of Oncology · Sites in Italy
Ages 18+
Women's Cancer Study Group GmbH · Sites in Germany
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
By country, each count listing its studies:
elacestrant: first FDA approval 2023 (ORSERDU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, elacestrant is the treatment under test here. Read study by study →
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 16 · Phase 3 4
First in 2015; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 478 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 72 across the 24 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stemline Therapeutics, Inc., one of the names counted as Menarini Group. Under that name alone:
Stemline Therapeutics, Inc. is the lead sponsor of 23 studies on the registry; 7 are open to participants now.
14 studies in Breast Neoplasms by Menarini Group: 4 open now, 8 under way, 1 of them phase 3. Of 6 finished, 2 (33%) have results posted.
Among the 14 studies in Breast Neoplasms by Menarini Group, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 2 in phase 3, and was the 4th registered.
Menarini Group’s Breast Neoplasms studies by the year they started, since 2015.
7 of the studies testing elacestrant in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05596409Stemline Therapeutics, Inc.ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | 2026-11 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT05982093SOLTI Breast Cancer Research GroupElacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | 2026-12 |
| NCT05563220Stemline Therapeutics, Inc.Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | 2026-12-27 |
| NCT07159451Gustave Roussy, Cancer Campus, Grand ParisA Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer | 2027-01-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 24 studies testing elacestrant in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Menarini Group’s 14 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI).
This is an international, multicenter, randomized, open-label, active-controlled, event-driven, Phase 3 clinical study comparing the efficacy and safety of elacestrant to the SoC options of fulvestrant or an aromatase inhibitor (AI) in postmenopausal women and in men with advanced or metastatic ER+/HER2- breast cancer, either in participants with tumors that harbor mutations in the ligand binding domain (LBD) of the estrogen receptor 1 (ESR1) gene (ESR1-mut participants) or in all participants regardless of ESR1 status (ESR1-mut and ESR1 wild type [ESR1-wt]) and whose disease has relapsed or progressed on at least one and no more than two prior lines of endocrine therapy (with documented progression), which must have included prior CDK4/6 inhibitor therapy in combination with fulvestrant or an aromatase inhibitor (AI) and for whom hormonal monotherapy with one of the SoC drugs (fulvestrant, anastrozole, letrozole, exemestane) is an appropriate treatment option.
Critical Inclusion Criteria:
Critical Exclusion Criteria:
Prior anticancer or investigational drug treatment within the following windows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Arm 1 will receive elacestrant.
Drug: Elacestrant
Participants in Arm 2 will receive investigator's choice of one of the standard-of-care drugs (fulvestrant, anastrozole, letrozole, or exemestane).
Drug: Standard of Care
400 mg/day once daily oral dosing
Also known as: RAD1901, ORSERDU
* Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle * Anastrozole 1 mg/day on a continuous dosing schedule * Letrozole: 2.5 mg/day on a continuous dosing schedule * Exemestane: 25 mg/day on a continuous dosing schedule
Also known as: Faslodex, Arimidex, Femara, Aromasin
This study also gives Fulvestrant, Anastrozole, Exemestane. No intervention listed here names it: that was found by reading the record.
Progression-free Survival in ESR1-mut Participants
Progression-free survival based on blinded IRC assessment in ESR1-mut participants defined as the length of time from randomization until the date of objective disease progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as assessed by the blinded IRC or death from any cause. Progression is defined per RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)
Progression-free Survival in All Participants
Progression-free survival based on blinded imaging review committee (IRC) assessment in all (ESR1-mut and ESR1-wt) participants.
Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)
Overall Survival in ESR1-mut Participants
Overall survival in ESR1-mut participants, where overall survival is defined as the length of time from randomization until the date of death from any cause.
Time frame: From Date of Randomization until Death Due to Any Cause (Estimated up to 24 Months)
Overall Survival in All Participants
Overall survival in all (ESR1-mut and ESR1-wt) participants.
Time frame: From Date of Randomization until Death Due to Any Cause (Estimated up to 24 Months)
| Milestone | Elacestrant | Standard of Care (SoC) |
|---|---|---|
| Started | 239 | 239 |
| Intent-to-treat population | 239 | 239 |
| Safety population | 237 | 230 |
| Completed | 152 | 130 |
| Not completed | 87 | 109 |
| Withdrew: Withdrawal by subject | 12 | 25 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Participant noncompliance | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Death | 69 | 79 |
Progression-free survival based on blinded IRC assessment in ESR1-mut participants defined as the length of time from randomization until the date of objective disease progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as assessed by the blinded IRC or death from any cause. Progression is defined per RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | Elacestrant | Standard of Care (SoC) |
|---|---|---|
| Progression-free Survival in ESR1-mut Participants | 3.78 (2.17 to 7.26) | 1.87 (1.87 to 2.14) |
Progression-free survival based on blinded imaging review committee (IRC) assessment in all (ESR1-mut and ESR1-wt) participants.
| months | Elacestrant | Standard of Care (SoC) |
|---|---|---|
| Progression-free Survival in All Participants | 2.79 (1.94 to 3.78) | 1.91 (1.87 to 2.10) |
Overall survival in ESR1-mut participants, where overall survival is defined as the length of time from randomization until the date of death from any cause.
| months | Elacestrant | Standard of Care (SoC) |
|---|---|---|
| Overall Survival in ESR1-mut Participants | NA (18.60 to NA) | 16.95 (14.00 to NA) |
Overall survival in all (ESR1-mut and ESR1-wt) participants.
| months | Elacestrant | Standard of Care (SoC) |
|---|---|---|
| Overall Survival in All Participants | NA (19.29 to NA) | NA (15.80 to NA) |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elacestrant | 70/239 (29.3%) | 29/237 (12.2%) | 215/237 (90.7%) |
| Standard of Care (SoC) | 80/239 (33.5%) | 25/230 (10.9%) | 195/230 (84.8%) |
| Event | Elacestrant | Standard of Care (SoC) |
|---|---|---|
| PneumoniaInfections and infestations | 1/237 | 3/230 |
| NauseaGastrointestinal disorders | 3/237 | 0/230 |
| Abdominal painGastrointestinal disorders | 0/237 | 2/230 |
| Urinary tract infectionInfections and infestations | 0/237 | 2/230 |
| VomitingGastrointestinal disorders | 2/237 | 0/230 |
| Small intestinal obstructionGastrointestinal disorders | 2/237 | 0/230 |
| Back painMusculoskeletal and connective tissue disorders | 2/237 | 0/230 |
| Spinal cord compressionNervous system disorders | 2/237 | 0/230 |
| ColitisGastrointestinal disorders | 0/237 | 1/230 |
| DiarrhoeaGastrointestinal disorders | 0/237 | 1/230 |
| Event | Elacestrant | Standard of Care (SoC) |
|---|---|---|
| NauseaGastrointestinal disorders | 83/237 | 44/230 |
| FatigueGeneral disorders | 45/237 | 44/230 |
| VomitingGastrointestinal disorders | 45/237 | 20/230 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/237 | 37/230 |
| Decreased appetiteMetabolism and nutrition disorders | 35/237 | 22/230 |
| DiarrhoeaGastrointestinal disorders | 33/237 | 22/230 |
| Back painMusculoskeletal and connective tissue disorders | 32/237 | 22/230 |
| Aspartate aminotransferase increasedInvestigations | 31/237 | 29/230 |
| ConstipationGastrointestinal disorders | 29/237 | 15/230 |
| HeadacheNervous system disorders | 29/237 | 26/230 |
| Age, Categorical(Participants) | Elacestrant | Standard of Care (SoC) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 135 | 128 | 263 |
| >=65 years | 104 | 111 | 215 |
| Sex: Female, Male(Participants) | Elacestrant | Standard of Care (SoC) | Total |
|---|---|---|---|
| Female | 233 | 238 | 471 |
| Male | 6 | 1 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Elacestrant | Standard of Care (SoC) | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 18 | 37 |
| Not Hispanic or Latino | 194 | 191 | 385 |
| Unknown or Not Reported | 26 | 30 | 56 |
| Height(cm) | Elacestrant | Standard of Care (SoC) | Total |
|---|---|---|---|
| Mean | 162.27 ± 7.860 | 160.97 ± 7.149 | 161.62 ± 7.532 |
| Weight(kg) | Elacestrant | Standard of Care (SoC) | Total |
|---|---|---|---|
| Mean | 72.70 ± 16.093 | 72.39 ± 16.390 | 72.55 ± 16.226 |
| Body Mass Index(kg/m^2) | Elacestrant | Standard of Care (SoC) | Total |
|---|---|---|---|
| Mean | 27.58 ± 5.494 | 27.92 ± 5.853 | 27.75 ± 5.673 |
| Eastern Cooperative Oncology Group Performance Status(Participants) | Elacestrant | Standard of Care (SoC) | Total |
|---|---|---|---|
| 0: Fully active, able to carry on all pre-disease performance without restriction | 143 | 135 | 278 |
| 1: Restricted in physically strenuous activity but ambulatory & can carry out light, sedentary work | 96 | 103 | 199 |
| 2: Ambulatory and capable of all selfcare but unable to carry out any work activities | 0 | 1 | 1 |
Showing the first 100 of 244 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from May 2019 to primary completion in Aug 2021, 27 months.
Results were first posted in Dec 2023, 2 years 3 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 27 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elacestrant